CD163 and neoplasm: We divided NPC patients into three subgroups based on EBV and HPV status (EBV−/HPV-, EBV+/HPV-, EBV+/HPV+) and investigated MIF, CD11c, CD68, and CD163 IF scores in tumor nest and tumor stroma.